Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. UroGen Pharma Ltd shares valued at $11,236 were sold by Schoenberg Mark on Sep 09 ’24. At $13.08 per share, Schoenberg Mark sold 859 shares. The insider’s holdings dropped to 145,091 shares worth approximately $1.6 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Smith Jason Drew sold 1,521 shares, netting a total of over 19,895 in proceeds. Following the sale of shares at $13.08 each, the insider now holds 25,226 shares.
Before that, Schoenberg Mark had added 859 shares to its account. In a trade valued at $11,365, the Officer bought UroGen Pharma Ltd shares for $13.23 each.
As published in their initiating research note from Guggenheim on August 22, 2024, UroGen Pharma Ltd [URGN] has been a Buy and the price target has been revised to $40. Analysts at Jefferies downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in early February. As of April 27, 2022, Berenberg has initiated its “Buy” rating for URGN. Earlier on April 16, 2020, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for URGN stock.
Analyzing URGN Stock Performance
During the last five days, there has been a surge of approximately 2.32%. Over the course of the year, UroGen Pharma Ltd shares have dropped approximately -26.40%. Shares of the company reached a 52-week high of $20.70 on 06/14/24 and a 52-week low of $10.26 on 12/23/24. A 50-day SMA is recorded $11.95, while a 200-day SMA reached $13.82. Nevertheless, trading volume fell to 0.6 million shares from 0.33 million shares the previous day.
Support And Resistance Levels for UroGen Pharma Ltd (URGN)
According to the 24-hour chart, there is a support level at 10.72, which, if violated, would cause prices to drop to 10.40. In the upper region, resistance lies at 11.22. The next price resistance is at 11.40. RSI (Relative Strength Index) is 39.90 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.44, which suggests the price will decrease in the coming days. Percent R is at 67.77%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of UroGen Pharma Ltd (URGN)?
On April 13, 2020, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $53.
